Company / Operating Income
BridgeBio Oncology Therapeutics, Inc. Operating Income History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$584.4K
FY2024
5-year range
-$584.4K / -$41.7K
FY2023-FY2024
Trend
-1301.7%
vs FY2023
Sector context
#56 of 204
Health Care
What the data says
At -$584,389, BridgeBio Oncology Therapeutics, Inc.'s operating income ranks #56 of 204 in the Health Care sector.
Based on SEC 10-K filings.
-$584,389 in FY2024.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#56 of 204 in Health CareTop 27% of 204This company -$584.4K Sector average $107.8M
▼
-100.5% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 1301.7% year-over-year.
- Ranks #56 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$584.4K | -1301.7% |
| FY2023 | -$41.7K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026